Borgeson Blake 4

What Happened

• Blake Borgeson, a director of Recursion Pharmaceuticals (RXRX), sold 30,000 shares on May 5, 2026.
• The shares were disposed in an open-market sale at $3.52 per share, totaling $105,600.
• This was a sale (routine disposition) rather than a purchase.

Key Details

• Transaction date and price: May 5, 2026 — 30,000 shares at $3.52 each.
• Total proceeds: $105,600.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: Transaction executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Borgeson on August 31, 2025 (pre-arranged plan).
• Filing: Form 4 filed May 7, 2026 for a May 5, 2026 transaction — appears timely (filed within the standard two-business-day window).

Context

• Sales under a 10b5-1 plan are pre-scheduled and common for insiders managing diversification or cash needs; they do not necessarily indicate a change in the insider’s view of the company.
• For retail investors, purchases typically carry more informational weight than routine sales; this filing documents a planned disposition rather than a new bullish stake.